We describe two patients with short-chain acyl-coenzyme A (CoA) dehydrogenase (SCADH) deficiency. Neonate 
Introduction
Deficiencies of the acyl-coenzyme A (CoA)' dehydrogenases (ADH) have only recently been identified in man. Patients with medium-chain acyl-CoA dehydrogenase (MCADH) deficiency ciency.
(MCD) often present with episodes of hypoketotic hypoglycemia and medium-chain dicarboxylic aciduria, although both sudden, unexpected death and clinical normalcy have been observed in homozygotes (1) . The presentation of long-chain acyl-CoA dehydrogenase (LCADH) deficiency (LCD) may also include hypotonia, hypertrophic cardiomyopathy, and early death (2) . Short-chain acyl-CoA dehydrogenase (SCADH) deficiency (SCD) has recently been found in muscle from a patient with lipid storage myopathy (3) and proposed in a second patient excreting ethylmalonate whose fibroblasts poorly oxidized shortchain fatty acids (4) .
We describe here two unrelated patients, both ofwhom presented with neonatal metabolic acidosis and ethylmalonate excretion. These observations suggested defective short-chain acylCoA dehydrogenation, since ethylmalonic and methylsuccinic acids can be formed from accumulated intramitochondrial butyryl-CoA. Butyryl-CoA is carboxylated by propionyl-CoA carboxylase to form ethylmalonyl-CoA, which is either hydrolyzed to ethylmalonic acid or converted to methylsuccinyl-CoA by methylmalonyl-CoA mutase, yielding in both cases methylsuccinic acid on hydrolysis (5, 6) . Although these metabolites have been noted in patients with other inborn errors of metabolism, notably the multiple acyl-CoA dehydrogenation disorders (MAD; references 5-7), prominent excretion of ethylmalonate in our patients suggested SCADH deficiency. This enzyme catalyzes the first step in the 13-oxidation of short-chain (4 and 6 carbon chain length fatty acids [C4-C6]) fatty acyl-CoAs.
This report summarizes clinical and biochemical studies on these SCD patients, the first in whom the defect is detected in fibroblasts. We demonstrated SCADH deficiencies by both an electron-transfer flavoprotein (ETF)-linked dye-reduction assay (8) and a tritium release ADH assay using [2, substrates (9) . The SCD patient described by Turnbull et al. (3) has normal SCADH activity in fibroblasts, which raises the possibility that a distinct SCADH isoenzyme exists in mammalian muscle.
Methods

Case histories NEONATE I (L.N.)
This female was born at 6 lb 14 oz after a full-term uncomplicated pregnancy to a healthy 33-yr-old mother with one living child. Delivery was assisted with forceps after an episode of deceleration. Apgar scores were 9 and 9 at 1 and 5 min and there was meconium staining of skin and cord. No problems were noted in the nursery. The parents were not consanguineous and there was no family history suggestive of metabolic or other genetic disorders. The infant was breast fed from birth. At age 6 d, after a 3-d history of poor feeding and listlessness and 1 d of hyperpnea, she was found to be lethargic and admitted to the Stanford University Neonatal Intensive Care Unit with a heart rate of 180 bpm, temperature 36.50C, blood pressure normal, and extremities pale and mottled. The infant had poor skin turgor, sunken eyes, and fontanelle. Laboratory data (normal values in parentheses) was arterial pH 7.03 (7.35-7 .45 pH), with calculated HCO3 3 meq/liter (22-26 meq/liter); Na, 166 meq/liter (135-145 meq/liter); K, 5.8 meq/liter (3.5-5.0 meq/ liter); and glucose, 94 mg/l00 ml (65-110 mg/l00 ml). 2 h later bloodurea nitrogen was 51 mg/100 ml (I10-20 mg/100 ml), creatinine 1.3 mg/ 100 ml (0.7-1.4 mg/l00 ml), and anion gap 31 meq/liter (10) (11) (12) (13) (14) (15) meq/ liter). Urine pH was 6.5, with ketones negative, trace reducing substances and small glucose. Complete blood count showed a leukocyte count of 21,400 (4,800-10,100) with 62 polymorphonucleocytes (42-81 polymorphonucleocytes), 10 bands (0-6 bands), 14.4 g/liter hemoglobin (15-24 g/liter), and 655,000 platelets (I150,000-400,000 platelets); evaluation for infection, including blood, urine, spinal fluid cultures, and chest radiograph, were all normal. Samples ofurine for amino and organic acids were obtained at admission.
Urine amino acids showed mild elevations of aspartate, threonine, glutamine, proline, glycine, alanine, and histidine (data not shown). Organic acids revealed highly elevated ethylmalonic acid (Table I) were begun and she tolerated increases to a regular diet of breast milk without recurrence of signs or symptoms of acidosis. A repeat urine 2 wk after presentation continued to show highly elevated ethylmalonic and methylsuccinic acids with normal adipic and without detectable glutaric, suberic, sebacic, azelaic, or hydroxydecanedioic acids. Over the next 4 mo she gained weight and attained developmental milestones normally while on a breast milk and soy formula diet.
To elucidate the nature of her metabolic block, a series of challenges with leucine, lysine, medium-chain triglycerides (MCT), and glycine was proposed. In the MAD (5-7), isovaleric, glutaric, and medium-chain dicarboxylic acid excretion would be expected to rise after challenges with the first three precursors, respectively. In MCD, only the MCT challenge would provoke a dicarboxylic aciduria. Concomitant glycine administration may promote excretion of specific acyl-glycines derived from accumulated acyl-CoAs and aid identification of the pathways involved (5, 10 , while urine organic acids were followed daily. The second set of challenges followed a l-wk rest and repeat baseline studies. Lysine (60 mg/kg per dose) was given t.i.d. for 2 d and was followed by analysis for urinary organic acids. After a l-d rest and a repeat baseline sample for organic acids, leucine (100 mg/ kg) was given in a single dose, and there was evaluation of plasma amino acids and urine organic acids at 2 and 6 h, respectively. Nonvolatile urinary organic acids were analyzed by sequential liquid partition chromatography, gas chromatography, and gas chromatography-mass spectrometry as previously described (11) . Results This female was born to a white female at 39 wk of gestation. The pregnancy was uneventful except for a history of nausea, vomiting, and diarrhea of viral origin in the mother and her family in the month before this birth. The mother was of Italian and Portuguese extraction and the father of French Canadian extraction; they have five normal male children. The baby was born by spontaneous vaginal delivery while the mother was under local anesthesia with Apgar scores of 9 and 9 at I and 5 min, respectively. The baby had a normal physical examination, and cow's milk formula feeding was started on day 2. On the 3rd day, the baby fed poorly, began to vomit, became lethargic and hypertonic. The respiratory rate was 60 and the liver extended 3 cm below the right costal margin. The rest of the exam was normal.
Laboratory tests included (normal values in parentheses): blood sugar, 38 mg/100 ml (65-110 mg/100 ml; subsequently normal on intravenous glucose); bilirubin, 8/0.9 mg/100 ml (0. On day 5, the electroencephalogram was worse, a brain scan showed little blood flow, the baby had fixed dilated pupils, and had no spontaneous activity or response to stimuli. With the family's permission, biopsies were taken of liver and skin and support was discontinued on the 6th day of life. Portmortem exam showed cerebral edema, hepatomegaly with fatty changes (microvesicular fat, intracanalicular cholestasis, and focal hepatocellular necrosis), thymic involution, and early bronchopneumonia. Bacterial and viral cultures were negative. -isovaleric acids were synthesized by New England Nuclear; the corresponding acyl-CoA esters were synthesized by the mixed anhydride method described previously (12) . Phenazine methosulfate (5-methylphenazinium methyl sulfate), flavin adenine dinucleotide (FAD; riboflavin5'-adenosine diphosphate), and N-ethylmaleimide were purchased from Sigma Chemical Co., St. Louis, MO. Pure pig liver MCADH, SCADH, and ETF were gifts from Dr. Carole L. Hall, Georgia Institute of Technology, Atlanta, GA; the pure pig kidney MCADH used for antisera preparation was a gift from Dr. Colin Thorpe Oxidation studies. '4C-Labeled substrate oxidation to 14C02 by intact fibroblasts in suspension was performed as described earlier (6, 8 (13) .
[3H]Palmitate oxidation to 3H20 by fibroblast monolayers was performed as described previously (14).
ADH and ETF assays. Both fibroblast mitochondrial and cellular sonic supernatants were prepared by the methods described earlier (8, 9) . The dye reduction ADH and ETF assays in mitochondrial supernatants and tritium release ADH assays in cell supernatants were described previously (7) (8) (9) 15 246±9 0±0 SCADH and MCADH activities were measured as previously described (8) . In the indicated experiments, 5 gl of monospecific rabbit antisera to pig kidney MCADH was incubated with either pure pig liver SCADH (3.5 pmol flavin) or MCADH (1.6 pmol flavin) for 5 min at 30'C before addition of substrate. Reaction was initiated with 440 pmol ETF. The results of two separate experiments were combined. [2,3-3H] acyl-CoAs as substrates and has been described previously (9, 12) . Enzymatic removal of tritium from carbons 2 and 3 of the substrate forms 3H20, which is separated quantitatively from unreacted substrate by anion exchange chromatography and lyophilization. SCADH, MCADH, and isovaleryl-CoA dehydrogenase activities in the patients' cell sonicates were measured using [2,3-3H]butyryl-, -octanoyl-, and -isovaleryl-CoAs. Neonates I and II had SCADH activities 41 and 53% ofcontrol (P < 0.01), while MCADH activities were 59 and 95% of control (P < 0.1), respectively. Fibroblasts from the previously reported adult patient with skeletal muscle SCADH deficiency (B.H. [3] ) had SCADH and MCADH activities 94% of control (Table V) . The tritium release assay in mitochondrial supernatants showed SCADH and MCADH activities in neonate I to be 57 and 66% of control, similar to values in cell sonicates (data not shown).
Mitochondrial ADH activities assayed by the dye reduction method yielded analogous results in both patients (data not shown for cell sonicates). SCADH activities in neonates I and II were 37 and 47% ofcontrol, respectively (P < 0.01); MCADH activities in neonates I and II were 56% (P < 0.01) and 81% of control, respectively (P > 0.2). Long-chain acyl-CoA dehydrogenase (LCADH) activities were > 75% of control in both patients (Table VI) . The low MCADH activities in neonate I, unexpected in isolated SCADH deficiency, might be explained by an endogenous inhibitor of MCADH and/or SCADH accumulating in her cells. However, mixing neonate I and control mitochondrial supernatants yielded SCADH and MCADH activities identical to the predicted values, which argues against this possibility (data not shown). The apparent Michaelis constants (Kin) of mitochondrial MCADH towards octanoyl-CoA in both neonates I and II and controls were similar (1-3 MM).
In neonate I, the apparent maximum velocity (V.,,) with octanoyl-CoA was 60% ofcontrol, consistent with the data reported in Table VI (other data not shown). Deficient ADH activities might result from low intramitochondrial pools of FAD in vivo. However, addition of 20 ALM FAD to cell or mitochondrial sonicates did not alter SCADH and MCADH activities in either neonate or controls (Table V; other data not shown). ETF activities were also normal (> 68% of control, P > 0.2) in both neonates (Table VII) .
Residual butyryl-CoA dehydrogenation in both patients is Mitochondria were isolated and ETF activity was measured as previ- ously described (7) . The number of determinations was 10 for five control lines and 4 to 5 for each patient line.
in the lipomyopathy patient of Turnbull et al. (3) . Although we readily demonstrated deficient SCADH activity in our patients, the residual enzymatic activities with butyryl-CoA was larger than anticipated for an isolated enzymatic defect. The high residual SCADH activities in these neonates probably resulted from overlapping chain length substrate specificities of human fibroblast ADHs, in analogy to other mammalian ADHs. While highly purified rat liver MCADH is relatively specific for C6-C8 acylCoAs, with little activity toward C4 substrates (19) (20) (21) , bovine MCADH and LCADH both show some activity towards butyrylCoA (20) .
While the chain length specificities of human ADHs are not known, we and others have evidence that human fibroblast MCADH can dehydrogenate butyryl-CoA. In patients with isolated MCADH deficiency (< 10% of control activity), fibroblast apparent SCADH activities are as low as 42% of control (1, 8, 9) , presumably reflecting the loss of MCADH activity towards butyryl-CoA. We inhibited MCADH with monospecific antisera, thereby removing its contribution to butyryl-CoA dehydrogenation and accurately defining butyryl-CoA dehydrogenation of SCADH. Octanoyl-CoA dehydrogenation by MCADH was completely inhibited in both neonates and controls by MCADH antisera, demonstrating that 43% of butyryl-CoA dehydrogenation in normal fibroblasts is catalyzed by MCADH. In the presence of MCADH antisera, neonates' I and II SCADH activities fell to 1 
